Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Isis Initiates Phase 3 Infant SMA Study

August 4, 2014 2:40 pm | News | Comments

Isis Pharmaceuticals Inc. announced the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA), the most common genetic cause of infant mortality. Read more...           

TOPICS:

Jentadueto Gets Label Update with New Trial Info

August 4, 2014 2:27 pm | News | Comments

The U.S. Prescribing Information for Jentadueto tablets now includes clinical trial data that showed linagliptin co-administered with metformin provided statistically significant decreases in blood glucose compared with linagliptin alone. Read more...

TOPICS:

Final Patient Treated in Phase 2 ALS Stem Cell Trial

August 4, 2014 2:06 pm | News | Comments

Neuralstem Inc. announced that the final patient was treated in its Phase 2 trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis, ALS or Lou Gehrig's disease. Read more...       

TOPICS:
Advertisement

Roche to Acquire Santaris Pharma

August 4, 2014 1:52 pm | News | Comments

Roche announced that it has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark. Read more...                             

TOPICS:

NIH's Fauci Says Ebola Vaccine Not Far Away

August 4, 2014 1:40 pm | News | Comments

The nation's top infectious disease official says there's hope that a vaccine against Ebola will be available as early as next July. Dr. Anthony Fauci of the National Institutes of Health says such a preventive vaccine has been successfully tested with monkeys. Read more...

TOPICS:

Medivir Licenses RSV Drug Program from BI

August 4, 2014 10:42 am | News | Comments

Medivir AB announced that it has entered a license agreement with Boehringer Ingelheim International GmbH for exclusive, global rights to a drug program for the treatment and prevention of Respiratory Syncytial Virus (RSV) infection. Read more...

TOPICS:

Multiple Myeloma Drug Meets Primary Endpoint

August 4, 2014 10:37 am | News | Comments

Amgen and its subsidiary, Onyx Pharmaceuticals, announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival. Read more...

TOPICS:

FDA Approves Lilly, BI Diabetes Drug

August 4, 2014 10:20 am | News | Comments

Federal regulators have approved a new treatment from U.S. drugmaker Eli Lilly and Co. and its German counterpart, Boehringer Ingelheim, for the most common form of diabetes, type 2, which accounts for more than 90% of the diabetes cases diagnosed in the United States. Read more...

TOPICS:
Advertisement

EMA, FDA Grant Glioblastoma Drug Orphan Drug Designation

August 4, 2014 10:12 am | News | Comments

AbbVie announced the EMA and the FDA have granted orphan drug designation to AbbVie's investigational compound ABT-414, an anti-epidermal growth factor receptor antibody drug conjugate, which is being evaluated for safety and efficacy in patients with glioblastoma multiforme. Read more...

TOPICS:

Capsaicin May Inhibit Gut Tumors

August 4, 2014 10:06 am | News | Comments

Researchers at the University of California, San Diego School of Medicine report that dietary capsaicin – the active ingredient in chili peppers – produces chronic activation of a receptor on cells lining the intestines of mice, triggering a reaction that ultimately reduces the risk of colorectal tumors. Read more...

TOPICS:

Allergan Sues Valeant, Cries Fraud

August 4, 2014 10:00 am | by Linda A. Johnson, AP Business Writer | News | Comments

Botox and eye-drug maker Allergan is suing a Canadian drugmaker and a hedge fund over their hostile takeover attempt, alleging insider trading and other fraud before their plan became public, and Valeant and Pershing Square call Allergan's claims related to tender offer rules "baseless." Read more...

TOPICS:

Sirona Biochem Synthesizes New Anti-Inflammatory

July 31, 2014 2:28 pm | News | Comments

Sirona Biochem Corp. announced the achievement of the first batch of compound in the joint venture with Bloom Burton & Co. Compounds developed within the framework of the joint venture (JV) will be entering development in the areas of rare inflammatory and infectious diseases. Read more...

TOPICS:

BGI Buys Genome Mapping System

July 31, 2014 2:21 pm | News | Comments

BioNano Genomics announced the purchase of an Irys System by BGI, the world's largest genomics organization. BGI selected BioNano's platform to enable comprehensive exploration of human structural variation and to provide vastly improved assemblies for various organisms of interest, including those where no reference exists. Read more...

TOPICS:

Replikin Count Predicts Ebola Outbreaks

July 31, 2014 2:14 pm | News | Comments

Replikins Ltd. released new data on changes in the gene structure of the Ebola virus showing that before the current outbreaks, the mean Ebola Reston gene Replikin Count between 1995 and 2002 was 1.1; the mean Replikin Count increased two-fold in 2010, three-fold in 2012, and sixteen-fold in 2013. Read more...

TOPICS:

Transplantation Works Well in Immunodeficient Children

July 31, 2014 2:07 pm | News | Comments

Babies who are born with severe combined immunodeficiency can be successfully treated with a transplant of blood-forming stem cells, according to experts led by Memorial Sloan Kettering’s Richard O’Reilly, MD, a world-renowned pioneer in the development of transplant protocols. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading